bluuebunny/crossref_metadata_2025_split huggingface dataset:
Cytoskeletal binding of monoclonal anti‐dna antibodies derived from tonsillar lymphoid cells of a normal subject
Authors: Cairns EWA , Komar Ronald , Bell David A. 
Published: February 2007

AbstractThe ability of monoclonal IgM anti‐DNA auto‐antibodies derived from normal human lymphoid cells to bind to cellular constituents of human epithelial cells (HEp‐2) was examined by immunofluorescence. Hybridoma supernatants from 10 different clones were studied. Four of them gave a strong fibrillar cytoplasmic staining that resembled cytoskeletal staining, 1 showed strong nuclear staining only, 3 showed weak nucleolar staining only, and 2 showed no staining. The hybridoma supernatants that reacted with HEp‐2 cytoskeleton were either polyspecific for various nucleic acid antigens, such as single‐stranded DNA, DNA, poly(dA:dT), poly(dG)·poly(dC), RNA, and cardiolipin, or were restricted to cardiolipin. Cytoskeletal staining identical to the hybridoma supernatant staining was also seen with mouse monoclonal anti‐vimentin antibody B11.5.1. Inhibition of the cytoskeletal staining was accomplished in 3 of the 4 hybridoma supernatants by preabsorption of these hybridoma supernatants with cardiolipin and/or single‐stranded DNA, or by preincubation of the HEp‐2 cells with the mouse monoclonal anti‐vimentin antibody.
PREVALENCE OF COXSACKIE B VIRUS ANTIBODIES IN PATIENTS WITH JUVENILE DERMATOMYOSITIS
Authors: Christensen MARY L. , Pachman Lauren M. , Schneiderman Richard , Patel Devendrakumar C. , Friedman Jan M. 
Published: February 2007

AbstractA number of viruses have been implicated as being the cause of various forms of myositis, including acute transient myositis, chronic polymyositis, and dermatomyositis. However, the cause of juvenile dermato‐myositis (JDM) has remained elusive. Our study of serum samples taken within 4 months of the onset of disease in 12 children with JDM showed that 83% had detectable titers of complement‐fixing (CF) antibody to 1 or more coxsackie B viral antigens. Detectable titers were found in only 25% of age‐, sex‐, and date‐matched control sera taken from 24 patients with juvenile rheumatoid arthritis (JRA), and in 25% of serum samples taken from 2,192 “normal” children who had been hospitalized because of viral syndromes. Titers of CF antibody to coxsackie B1, B2, and B4 were positive in 58%, 50%, and 58%, respectively, of the JDM patients. In matched JRA controls, the respective values were 8%, 13%, and 8%. There were no significant antiviral titers and no significant differences in the results of tests for 13 other viral CF antigens, hepatitis B surface antigen, and Mycoplasma pneumoniae CF antigen in the JDM patient sera compared with the JRA patient sera. When titers of neutralizing antibody were determined, 58%, 58%, and 67% of the JDM patients were positive for coxsackie B2, B4, and B5, respectively, whereas 16%, 26%, and 21%, respectively, of the JRA controls were positive for the 3 antigens. These data suggest that the host response to coxsackie B virus might be related to the pathophysiology of JDM.
A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia
Authors: Goldenberg Don L. , Felson David T. , Dinerman Hal 
Published: February 2007

AbstractSixty‐two patients with fibromyalgia were randomly assigned to receive 25 mg of amitriptyline at night, 500 mg of naproxen twice daily, both amitriptyline and naproxen, or placebo in a 6‐week, double‐blind trial. Amitriptyline was associated with significant improvement in all outcome parameters, including patient and physician global assessments, patient pain, sleep difficulties, fatigue on awakening, and tender point score. Patients taking the combined naproxen—amitriptyline regimen experienced minor, but not significant, improvement in pain when compared with patients who took amitriptyline alone. Amitriptyline, or amitriptyline and naproxen, is an effective therapeutic regimen for patients with fibromyalgia.
In vitro synthesis of IgM rheumatoid factor in response to STAPHYLOCOCCUS AUREUS, by lymphocytes from healthy adults
Authors: Goldstein Rose , Karsh Jacob 
Published: February 2007

AbstractPeripheral blood mononuclear cells from 20 healthy adults were tested in vitro for the production of IgM rheumatoid factor (RF) in response to Staphylococcus aureus Cowan I (SAC) or pokeweed mitogen. Fifteen of the 20 normal subjects produced ⩾4 ng/ml IgM‐RF (mean ± SD 46 ± 55 ng/ml) in response to SAC, compared with only 2 of 20 who produced ±4 ng/ml IgM‐RF (mean ± SD 2 ± 4 ng/ml) in response to pokeweed mitogen (P = 0.0001). Separation and reconstitution of autologous T and B cell‐enriched fractions, with and without prior T cell irradiation, provided evidence for a radiosensitive T helper/inducer cell involved in the IgM‐RF response to SAC in 70% of the normal subjects studied. SAC appears to be a potent stimulus of IgM‐RF production, with a cellular mechanism distinct from that of other in vitro systems.
Hypocomplementemia with low Cls‐Cl inhibitor complex in systemic lupus erythematosus
Authors: Lockshin M. D. , Qamar Tasneem , Redecha Patricia , Harpel P. C. 
Published: February 2007

AbstractNinety‐three serum and plasma samples from 45 patients with systemic lupus erythematosus were analyzed for the complex formed by Cls and its inhibitor, as well as for C3, C4, C4a desarginine, and staphylococcal protein A‐bound immune complexes. There were statistically significant correlations between Cls‐Cl inhibitor complex and CH50, between Cls‐Cl inhibitor complex and C4, and between Cls‐Cl inhibitor complex and C4a desarginine. Serial studies were performed on 24 patients over a period of 6 months. Seven of 21 patients with hypocomplementemia had persistently normal levels of Cls‐Cl inhibitor complex, 7 had transiently abnormal levels of Cls‐Cl inhibitor complex, and 7 had sustained abnormal levels of Cls‐Cl inhibitor complex. Two of 3 pregnant patients with normal levels of complement had abnormal levels of Cls‐Cl inhibitor complex. Staphylococcal protein A‐bound immune complexes demonstrated no correlation with any of the complement assays. Complement activation, as measured by Cls‐Cl inhibitor complex, is often a transient phenomenon in systemic lupus erythematosus patients with persistent hypocomplementemia.
Ankylosing spondylitis in families with two distinct B27 haplotypes: A selective association
Authors: Suarez‐Almazor Maria E. , Russell Anthony S. , Leclercq Sharon 
Published: February 2007

AbstractFive families whose members had 2 distinct B27 haplotypes, and in which numerous members had ankylosing spondylitis (AS), were studied to see whether, in each family, both B27 haplotypes were associated with similar risks for the development of AS. In 4 of the 5 families, all family members with AS (4, 2, 3, and 2 individuals, respectively) shared the same B27 haplotype; however, 1 was homozygous for HLA‐B27 and carried both haplotypes. By statistical analysis, we showed that the B27 haplotype carried by the eldest member with AS in each family was more likely to be associated with disease. If additional genetic factors play a role in the development of AS, these preliminary findings suggest that they are probably located around the major histocompatibility complex.
Association between HLA and Sjögren's syndrome in Japanese patients
Authors: Moriuchi Junko , Ichikawa Yukinobu , Takaya Masatoshi , Shimizu Hiroaki , Uchiyama Mitsuaki , Sato Kaoru , Tsuji Kimiyoshi , Arimori Shigeru 
Published: February 2007

AbstractJapanese patients with primary Sjögren's syndrome (SS), patients with SS and rheumatoid arthritis (SS‐RA), and patients with SS and connective tissue disease without RA (nonrheumatoid connective tissue disease [SS‐CTD]) were typed for HLA antigens. Patients with primary SS and those with SS‐RA had higher frequencies of DRw53 than did those who had SS‐CTD; however, the group with SS‐CTD showed a negative correlation with DRw52. These data indicate that Japanese and white patients with SS have different HLA specificities, and that genetic factors involved in the development of SS‐CTD might be different from those in primary SS and SS‐RA.
The natural history of fibromyalgia
Authors: Felson David T. , Goldenberg Don L. 
Published: February 2007

AbstractThe natural history of fibromyalgia was studied in 39 treated patients. All patients were surveyed by interviews conducted in 1983 (at an average of 1.3 years after diagnosis), in 1984, and again in 1985. Throughout the survey period, more than 60% of patients had moderate to severe continuing symptoms, and almost all took medications regularly to control symptoms. Younger patients (P = 0.02), those with less severe symptoms at the initial survey (P = 0.005), and those with isolated Raynaud's phenomenon (P = 0.04) were more likely to be doing well 2 years later, although symptom remission was usually transitory.
Long‐term followup of rheumatoid arthritis patients treated with total lymphoid irradiation
Authors: Tanay A. , Field E. H. , Hoppe R. T. , Strober S. 
Published: February 2007

AbstractTotal lymphoid irradiation was administered to 32 patients with intractable rheumatoid arthritis. Twenty‐four patients showed at least a 25% improvement in 3 of 4 disease activity parameters, which persisted during the followup period of up to 48 months. Eight of the 32 patients required adjunctive immunosuppressive drug therapy to maintain improvement. Four patients died after total lymphoid irradiation; the causes of death were acute myocardial infarction (1 patient), pulmonary embolism (1 patient), and rheumatoid lung disease complicated by respiratory infection (2 patients). After therapy, patients exhibited a prolonged reduction in the number and function of circulating T helper cells.
Cyclosporin A Treatment of Refractory Rheumatoid Arthritis
Authors: Weinblatt Michael E. , Coblyn Jonathan S. , Fraser Patricia A. , Anderson Ronald J. , Spragg Jocelyn , Trentham David E. , Austen K. Frank 
Published: February 2007

AbstractTen patients with rheumatoid arthritis were entered into a 24‐week pilot study of oral cyclosporin A at a starting dosage of 6 mg/kg/day, followed by a 12‐week washout period. Significant improvement in clinical parameters was observed at 12 weeks and 24 weeks (P < 0.02 versus baseline for joint pain and joint swelling indexes and patient and physician assessments; P < 0.04 versus baseline in the numbers of painful/tender joints and swollen joints). Adverse reactions were varied: renal impairment occurred in all patients and hypertension occurred in 7. All patients demonstrated an increase in defined disease activity at cessation of treatment and through the washout period. Cyclosporin A is clinically effective in the treatment of patients with refractory rheumatoid arthritis, but its value as an intervention therapy is limited by its toxicity.
Immunohistochemical characterization of synovial cells in arthritic mrl‐lpr/lpr mice
Authors: Tarkowski Andrej , Jonsson Roland , Holmdahl Rikard , Klareskog Lars 
Published: February 2007

AbstractMRL‐lpr/lpr (MRL/l) mice spontaneously develop an autoimmune disease associated with arthritic manifestations. We used a recently developed mild demineralization procedure, followed by immunohistochemical staining of frozen sections, to investigate cell patterns in the hindlimbs of MRL/l mice at various stages of arthritic disease. Large numbers of Mac‐1 (Mas 034)–positive, macrophage‐like cells were seen both within the thickened synovial lining layer and in the deeper layers of the synovial tissue in all stages of arthritis. Ia‐expressing cells were scarce in the lining layer, but occurred in moderate numbers in the deeper layers of synovial tissue. Lymphocytes were totally absent in MRL/l joints in all stages of arthritis, as demonstrated by lack of staining with Ly‐1, Lyt‐2, GK 1,5, and antiimmunoglobulin antibodies. Our findings are discussed and related to other types of experimental arthritis and to rheumatoid arthritis in humans.
Evidence of the validity of the arthritis impact measurement scales
Authors: Potts Marilyn K. , Brandt Kenneth D. 
Published: February 2007

AbstractThe Arthritis Impact Measurement Scales (AIMS) were administered to 120 patients with rheumatoid arthritis. These patients also rated the importance of various aspects of their treatment. Our findings support the validity of the pain, anxiety, depression, dexterity, and physical activity subscales of the AIMS. The household activity subscale, however, may not be appropriate for use with men, and the activities of daily living subscale may be insensitive to mild impairment.
Nuclear ribonucleoprotein immune complexes in pericardial fluid of a patient with mixed connective tissue disease
Authors: Negoro Nobuo , Kanayama Yoshiharu , Yasuda Mitsutaka , Okamura Mikio , Amatsu Koji , Koda Shinichi , Takeda Tadanao , Inoue Takatoshi 
Published: February 2007

AbstractWe performed immunopathologic studies of the pericarditis present in a patient with mixed connective tissue disease. A large number of nuclear RNP (nRNP) immune complexes (ICs) were found in the pericardial fluid, but not in the serum. The pericardial small vessels had no deposits of IgG. These results suggest that locally formed nRNP ICs were closely associated with the pathogenesis of pericarditis in this patient.
A controlled study of concurrent therapy with a nonacetylated salicylate and naproxen in rheumatoid arthritis
Authors: Furst Daniel E. , Blocka Kenneth , Cassell Sidney , Harris E. Robert , Hirschberg Joel M. , Josephson Nathan , Lachenbruch Peter A. , Trimble R. Bruce , Paulus Harold E. 
Published: February 2007

AbstractPrevious studies of combinations of nonsteroidal drugs used in the treatment of rheumatoid arthritis (RA) have yielded conflicting results. We used standard methods to measure disease activity and high pressure liquid chromatography to measure plasma drug concentrations. We used doses of choline magnesium trisalicylate, adjusted to achieve therapeutic serum salicylate concentrations, and naproxen in a randomized, double‐blind, placebo‐controlled cross‐over study of full dose trisalicylate (CMT), full dose naproxen (N), full dose of both (CMT‐N), and half dose of both (cmt‐n) to examine their relative efficacy and toxicity in treating RA. CMT‐N was statistically superior to all other treatments in only 1 of 12 efficacy variables, but was equal to N and better than CMT or cmt‐n for 7 variables. There were minimal differences among treatments for the other 4 efficacy variables. The mean percentage difference for the efficacy variables between CMT‐N and N was 3%, between CMT‐N and CMT was 10.6%, and between CMT‐N and cmt‐n was 10.5%. Thirteen percent of patients manifested toxic reactions during the initial open dose‐adjustment salicylate run‐in phase. During the double‐blind phases of the study, CMT‐N was more toxic than N, CMT, or cmt‐n (7.5% versus 3.4%, 1.8%, and 3.7%, respectively). Tinnitus was more common when full‐dose CMT was used; N (N or CMT‐N) was associated with increased skin toxicity. Gastrointestinal complaints were equally common with all regimens. CMT‐N, although sometimes statistically superior to CMT, N, or cmt‐n, showed no clinically important additive or synergistic effect versus N or CMT alone.
Non‐hodgkin's lymphoma of the synovium simulating rheumatoid arthritis
Authors: Dorfman Howard D. , Siegel Howard L. , Perry Michael C. , Oxenhandler Ronald 
Published: February 2007

AbstractSkeletal involvement in patients with non‐Hodgkin's lymphoma (NHL) is common, although direct involvement of the joints is unusual. We describe 2 adults who presented with features suggestive of a diagnosis of rheumatoid arthritis, but who were found to have diffuse NHL of the synovium. Results of a review of the literature, and assessment of the few similar cases in which NHL presented in the joint, suggest that the lymphoma may mimic either a monarticular or polyarticular synovitis, without lymphadenopathy or hepatosplenomegaly. Radiographic demonstration of associated bone destruction is the best evidence for non‐Hodgkin's lymphomatous arthropathy in patients with rheumatic symptoms.
Detection of antibodies to total histones and their subfractions in systemic lupus erythematosus patients and their asymptomatic relatives
Authors: Shoenfeld Y. , Segol G. , Segol O. , Neary B. , Klajman A. , Stollar B. D. , Isenberg D. A. 
Published: February 2007

AbstractSera drawn from 75 patients with systemic lupus erythematosus, 141 healthy relatives (from the families of 51 patients), and 115 healthy control subjects were examined, by enzyme‐linked immunosorbent assay, for IgG and IgM antibodies to total histones and their subfractions. Compared with the controls, statistically significant numbers of patients and their relatives had antihistone antibodies of both isotypes. Among the relatives, the sera from females, notably sisters of the patients, contained the highest levels of anti–total histone antibody. Anti‐H2A/H2B and H3 antibodies were most prevalent among the lupus patients, but many of the relatives had IgM anti‐H4 antibodies. These findings indicate that antihistone antibodies can serve as a genetic marker in patients with systemic lupus erythematosus.
Proteoglycan‐induced arthritis in balb/c mice
Authors: Glant Tibor T. , Mikecz Katalin , Arzoumanian Artin , Poole A. Robin 
Published: February 2007

AbstractImmunization with chondroitinase ABC–digested fetal human cartilage proteoglycan and Freund's complete adjuvant induced polyarthritis and ankylosing spondylitis in female BALB/c mice. The initial external symptoms of the joint inflammation were swelling and redness. This was associated with edema of the synovium and periarticular tissues and gross proliferation of cells, which reached a peak during weeks 7–9 of the experiment. Mononuclear cell infiltration, with perivascular concentration and occlusion of small vessels, was common. Synovitis increased in severity, villous pannus developed, and erosions of bone, articular cartilage, and occasionally, growth plate were observed. The lumbar spine and the proximal intervertebral discs of the tail also exhibited inflammatory and degenerative changes. As the arthritis progressed, sometimes with acute inflammatory exacerbations, more joints became involved and, by the sixteenth to the twentieth weeks of the experiment, a progressive polyarthritis, with gross joint deformities and restricted function, developed in the majority of the limb joints. Clinical and morphologic features of the disease correlated well with radiologic analysis and with an increased deposition of 99mTc–methylene diphosphonate (determined by radionuclide imaging). The development of this arthritis was accompanied by the expression of cell‐mediated and humoral immunity to the immunizing antigen. However, this immunity was also observed, although it was generally less well developed, in mice that received the intact or digested proteoglycan without adjuvant. These mice did not usually develop arthritis. Control mice that received only adjuvant did not develop arthritis.
Arthritis care in older‐adult centers
Authors: Mazzuca Steven A. , Barger Gloria J. , Brandt Kenneth D. 
Published: February 2007

AbstractIn this study, we evaluated an inservice training program for public health nurses. The training program concerned arthritis screening and management of the disease in elderly subjects. Twenty‐nine nurses were assigned randomly to experimental (training) or control conditions. Evaluation data from 158 interviews with patients showed that screening for arthritis was done twice as frequently by nurses in the experimental group, compared with that done by nurses who were not in the experimental group (P < 0.01). Recommended management of arthritis was not correspondingly improved. Stronger inservice programs are discussed in light of the need to anticipate seasonal conflicts between arthritis care and preventive care for the elderly, to change habitual practice patterns, and to increase access to arthritis health professionals.
Nicardipine in the treatment of raynaud's phenomenon
Authors: Wigley Fredrick M. , Wise Robert A. , Malamet Raymond , Scott Thomas E. 
Published: February 2007

AbstractA new calcium channel blocker, nicardipine, was studied for treatment of Raynaud's phenomenon in a double‐blind, placebo‐controlled, crossover trial during the winter months. Clinical response was assessed by a patient‐kept diary of symptoms and finger systolic pressure that was measured at room temperature and during cold challenge. In vivo platelet activation was determined by measuring plasma levels of the platelet‐specific proteins, beta‐thromboglobulin and platelet factor 4. When treatment with placebo was compared with treatment with nicardipine, no significant differences were found in the number of Raynaud's attacks per day, the severity of attacks, change in character in Raynaud's phenomenon, use of hands in winter months, patient assessment of medication or objective measurements of finger systolic pressure, and critical closing temperature. There was a reduction of plasma levels of beta‐thromboglobulin and platelet factor 4 in the overall study group while taking nicardipine compared with that during the placebo period (mean change 5.0 ± 2.4 ng/ml, P = 0.054, and 1.4 ± 0.6 ng/ml, P < 0.01, respectively). These results demonstrate that while nicardipine was not effective in reducing the episodes of Raynaud's phenomenon, it did inhibit in vivo platelet activation. These findings suggest that platelet activation is not the primary event in the pathogenesis of acute vasospasm in Raynaud's phenomenon, since reduction of platelet activation by the drug did not change the severity of vasospasm.
Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a danish county
Authors: Boesen Per , Sørensen Søren Freiesleben 
Published: February 2007

AbstractThe annual incidence of giant cell arteritis (the term used in this study to encompass the syndromes of temporal arteritis and polymyalgia rheumatica, occurring either together or alone) was prospectively determined in a Danish county that had a population of approximately 200,000. In a single year, 46 new cases of giant cell arteritis were diagnosed, a number which corresponds to an incidence in the overall population of 21.5/105, and to an incidence of 76.6/105 for individuals age 50 years or older. These rates are higher than those previously reported in retrospective studies. The 3‐year followup of all patients showed no onset of other diseases that would require a revision of the original diagnosis. There was no deviation from the age‐ and sex‐specific malignancy rate or the mortality rate in the overall population. Women had an incidence rate 4 to 5 times higher than that seen in men. Symptoms, for the most part, were the same as those found in other studies; however, vision loss was not observed during the followup period. Point prevalence at the start of the study was 37.8/105, which is below the rates previously reported. This is probably because of failure on the part of participating physicians to record all cases.